SCHOLAR ROCK HOLDING CORPORATION Payments to Acquire Marketable Securities
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Payments to Acquire Marketable Securities of $68.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for the quarter ending 2026-06-30 was $43.00M, a 102.64% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for the quarter ending 2026-03-31 was $25.27M, a 56.49% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for the quarter ending 2025-09-30 was $18.72M, a 31.25% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for fiscal 2025 was $98.01M, a 66.57% decline from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for fiscal 2024 was $293.16M, a 0.81% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for fiscal 2023 was $290.80M, a 3.27% decline from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION payments to acquire marketable securities for fiscal 2022 was $300.63M, a 397.43% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $68.27M 10-Q · filed 2026-08-06 | $68.27M derived: sum of 3 quarters · filed 2026-08-06 | $86.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $25.27M 10-Q · filed 2026-05-07 | $25.27M derived: sum of 2 quarters · filed 2026-05-07 | $43.98M derived: sum of 3 quarters · filed 2026-05-07 | $65.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $18.72M derived: sum of 2 quarters · filed 2026-03-03 | $39.94M derived: sum of 3 quarters · filed 2026-08-06 | $98.01M 10-K · filed 2026-03-03 |
| 2025-09-30 | $18.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $39.94M derived: sum of 2 quarters · filed 2026-08-06 | $98.01M 10-Q · filed 2025-11-14 | $308.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $21.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $79.29M 10-Q · filed 2026-08-06 | $289.74M derived: sum of 3 quarters · filed 2026-08-06 | $304.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $58.07M 10-Q · filed 2026-05-07 | $268.52M derived: sum of 2 quarters · filed 2026-05-07 | $282.78M derived: sum of 3 quarters · filed 2026-05-07 | $316.24M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $210.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $224.71M derived: sum of 2 quarters · filed 2026-03-03 | $258.17M derived: sum of 3 quarters · filed 2026-03-03 | $293.16M 10-K · filed 2026-03-03 |
| 2024-09-30 | $14.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $47.72M derived: sum of 2 quarters · filed 2025-11-14 | $82.71M 10-Q · filed 2025-11-14 | $186.84M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $33.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $68.45M 10-Q · filed 2025-08-06 | $172.58M derived: sum of 3 quarters · filed 2025-08-06 | $254.05M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $34.99M 10-Q · filed 2025-05-14 | $139.12M derived: sum of 2 quarters · filed 2025-05-14 | $220.59M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $104.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $185.60M derived: sum of 2 quarters · filed 2025-02-27 | $290.80M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $81.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $186.67M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $105.20M 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $9.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $220.50M derived: sum of 2 quarters · filed 2024-03-19 | $220.50M derived: sum of 3 quarters · filed 2024-03-19 | $300.63M 10-K · filed 2024-03-19 |
| 2022-09-30 | $210.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $210.69M derived: sum of 2 quarters · filed 2023-11-07 | $290.83M 10-Q · filed 2023-11-07 | $290.83M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $80.13M 10-Q · filed 2023-08-09 | $80.13M derived: sum of 3 quarters · filed 2023-08-09 | $110.44M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $80.13M 10-Q · filed 2023-05-09 | $80.13M derived: sum of 2 quarters · filed 2023-05-09 | $110.44M derived: sum of 3 quarters · filed 2023-05-09 | $110.44M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $30.31M derived: sum of 2 quarters · filed 2023-03-07 | $30.31M derived: sum of 3 quarters · filed 2023-03-07 | $60.44M 10-K · filed 2023-03-07 |
| 2021-09-30 | $30.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $30.31M derived: sum of 2 quarters · filed 2022-11-14 | $60.44M 10-Q · filed 2022-11-14 | $181.10M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $30.13M 10-Q · filed 2022-08-08 | $150.80M derived: sum of 3 quarters · filed 2022-08-08 | $210.84M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $30.13M 10-Q · filed 2022-05-16 | $150.80M derived: sum of 2 quarters · filed 2022-05-16 | $210.84M derived: sum of 3 quarters · filed 2022-05-16 | $210.84M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $120.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | $180.71M derived: sum of 2 quarters · filed 2022-03-07 | $180.71M derived: sum of 3 quarters · filed 2022-03-07 | $200.11M 10-K · filed 2022-03-07 |
| 2020-09-30 | $60.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $60.04M derived: sum of 2 quarters · filed 2021-11-09 | $79.44M 10-Q · filed 2021-11-09 | $120.25M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $19.40M 10-Q · filed 2021-08-10 | $60.21M derived: sum of 3 quarters · filed 2021-08-10 | $177.52M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $19.40M 10-Q · filed 2021-05-13 | $60.21M derived: sum of 2 quarters · filed 2021-05-13 | $177.52M derived: sum of 3 quarters · filed 2021-05-13 | $177.52M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $40.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $158.12M derived: sum of 2 quarters · filed 2021-03-09 | $158.12M derived: sum of 3 quarters · filed 2021-03-09 | $235.42M 10-K · filed 2021-03-09 |
| 2019-09-30 | $117.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $117.31M derived: sum of 2 quarters · filed 2020-11-09 | $194.61M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $77.30M 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | $77.30M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $75.24M 10-K · filed 2020-03-12 | |||
| 2018-03-31 | $23.41M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |